Last Week Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings

May 17, 2018 - By Joseph Norton

During 2017 Q4 the big money sentiment decreased to 1.2. That’s change of 0.53, from 2017Q3’s 1.73. 23 investors sold all, 48 reduced holdings as Aerie Pharmaceuticals, Inc. ratio dropped. 64 grew holdings while 21 funds acquired holdings. Funds hold 34.86 million shares thus 1.29% more from 2017Q3’s 34.42 million shares.
Castleark Management Llc holds 0.08% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 45,223 shs. Stifel Fincl Corp accumulated 0.02% or 85,458 shs. State Common Retirement Fund accumulated 35,200 shs. Moreover, Pictet Asset Limited has 0.05% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 318,164 shs. American Century holds 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) or 33,588 shs. Columbus Circle accumulated 593,086 shs. Senzar Asset Mngmt Ltd Llc invested 4.25% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Voya Inv Limited Liability Corp owns 397,928 shs for 0.05% of their capital. Pub Employees Retirement Association Of Colorado invested in 0% or 2,940 shs. Aperio Grp Ltd Liability Co stated it has 5,721 shs. Manufacturers Life Insur The holds 25,279 shs or 0% of its capital. Atlantic Group holds 0% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 500 shs. Phoenix Invest Adviser Limited Liability Company has 0.02% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Goldman Sachs Group Incorporated holds 0% or 157,977 shs in its capital. 6,787 were reported by First Mercantile Tru Communications.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

Total analysts of 6 have positions in Aerie Pharma (NASDAQ:AERI) as follows: 6 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 18, 2017 according to StockzIntelligence Inc Aerie Pharma has 11 analyst reports. On Thursday, March 29 Mizuho maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Wednesday, January 24 Canaccord Genuity maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Canaccord Genuity has “Buy” rating and $86.0 target. The stock rating was maintained by H.C. Wainwright with “Buy” on Wednesday, May 9. In Monday, December 18 report Cantor Fitzgerald maintained it with “Buy” rating and $77.0 target. On Wednesday, February 28 Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Cantor Fitzgerald has “Buy” rating and $86.0 target. On Tuesday, January 2 the firm earned “Buy” rating by Stifel Nicolaus. The stock rating was maintained by H.C. Wainwright with “Buy” on Thursday, March 1. On Friday, February 16 the firm earned “Buy” rating by H.C. Wainwright. On Tuesday, May 8 Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Cantor Fitzgerald has “Buy” rating and $8600 target. On Wednesday, May 9 the firm earned “Buy” rating by Mizuho. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

AERI hit $51.15 during the last trading session after $0.05 change.Aerie Pharmaceuticals, Inc. has volume of 226,563 shares. Since May 17, 2017 AERI has risen 16.25% and is uptrending. AERI outperformed the S&P500 by 4.70%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is worth $2.02 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

For more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news published briefly go to: Businesswire.com, Benzinga.com, Globenewswire.com, Gurufocus.com or Benzinga.com. The titles are as follows: “Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8 …” published on April 26, 2018, “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” on May 08, 2018, “Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie …” with a publish date: May 03, 2018, “9 Stocks Ron Baron Continues to Buy” and the last “Benzinga Pro’s 5 Stocks To Watch Today” with publication date: May 15, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.